JP7585195B2 - ネオエピトープを選択する方法 - Google Patents

ネオエピトープを選択する方法 Download PDF

Info

Publication number
JP7585195B2
JP7585195B2 JP2021517009A JP2021517009A JP7585195B2 JP 7585195 B2 JP7585195 B2 JP 7585195B2 JP 2021517009 A JP2021517009 A JP 2021517009A JP 2021517009 A JP2021517009 A JP 2021517009A JP 7585195 B2 JP7585195 B2 JP 7585195B2
Authority
JP
Japan
Prior art keywords
neoepitopes
mhc
binding
minimal
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021517009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502416A (ja
JP2022502416A5 (https=
JPWO2020065023A5 (https=
Inventor
セケーリヤ モニカ
シュイェトゥーヌ カロリーネ
ブルンスビク フレードリクセン アグネーテ
Original Assignee
ナイコード セラピューティクス アルメン アクスイェ セルスカプ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナイコード セラピューティクス アルメン アクスイェ セルスカプ filed Critical ナイコード セラピューティクス アルメン アクスイェ セルスカプ
Publication of JP2022502416A publication Critical patent/JP2022502416A/ja
Publication of JP2022502416A5 publication Critical patent/JP2022502416A5/ja
Publication of JPWO2020065023A5 publication Critical patent/JPWO2020065023A5/ja
Application granted granted Critical
Publication of JP7585195B2 publication Critical patent/JP7585195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30Detection of binding sites or motifs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021517009A 2018-09-27 2019-09-27 ネオエピトープを選択する方法 Active JP7585195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18197172.2 2018-09-27
EP18197172 2018-09-27
PCT/EP2019/076210 WO2020065023A1 (en) 2018-09-27 2019-09-27 Method for selecting neoepitopes

Publications (4)

Publication Number Publication Date
JP2022502416A JP2022502416A (ja) 2022-01-11
JP2022502416A5 JP2022502416A5 (https=) 2022-09-27
JPWO2020065023A5 JPWO2020065023A5 (https=) 2022-09-27
JP7585195B2 true JP7585195B2 (ja) 2024-11-18

Family

ID=63794302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517009A Active JP7585195B2 (ja) 2018-09-27 2019-09-27 ネオエピトープを選択する方法

Country Status (12)

Country Link
US (1) US12462898B2 (https=)
EP (1) EP3856957A1 (https=)
JP (1) JP7585195B2 (https=)
KR (1) KR102902460B1 (https=)
CN (1) CN112771214B (https=)
AU (1) AU2019346023B2 (https=)
BR (1) BR112021005702A8 (https=)
CA (1) CA3111903A1 (https=)
IL (1) IL281771B2 (https=)
MX (1) MX2021003654A (https=)
SG (1) SG11202101965QA (https=)
WO (1) WO2020065023A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
US20230197192A1 (en) * 2020-11-06 2023-06-22 Amazon Technologies, Inc. Selecting neoantigens for personalized cancer vaccine
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
IL305777A (en) 2021-03-26 2023-11-01 Nykode Therapeutics ASA Medical combination for cancer treatment
WO2022238420A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunostimulatory compounds
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2023244997A1 (en) * 2022-06-13 2023-12-21 The University Of North Carolina At Chapel Hill Compositions and methods for inducing anticancer immunity
EP4608436A1 (en) 2022-10-25 2025-09-03 Nykode Therapeutics ASA Constructs and their use
KR102857635B1 (ko) * 2022-11-08 2025-09-10 인바이츠지노믹스 주식회사 면역원성이 높은 유사체를 디자인하는 방법 및 이를 이용한 장치
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2024216073A1 (en) * 2023-04-14 2024-10-17 The Trustees Of Columbia University In The City Of New York Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy
US20250232833A1 (en) * 2024-01-13 2025-07-17 Noergaard Anders Kaare Cyclin D1 Based Cancer Vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507686A (ja) 2015-02-12 2018-03-22 バイオンテック エールエヌアー ファーマシューティカルズ ゲーエムベーハー ワクチン接種に有用なt細胞エピトープの予測
JP2018515519A (ja) 2015-05-13 2018-06-14 アジェナス インコーポレイテッド がんの処置および予防のためのワクチン
WO2018136664A1 (en) 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
JP2018524008A (ja) 2015-07-14 2018-08-30 パーソナル ジノーム ダイアグノスティクス, インコーポレイテッド ネオアンチゲン分析

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
JP6558699B2 (ja) 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン
US11186640B2 (en) 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
EP3193892A4 (en) 2014-09-14 2018-09-12 Washington University Personalized cancer vaccines and methods therefor
US10317402B2 (en) 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507686A (ja) 2015-02-12 2018-03-22 バイオンテック エールエヌアー ファーマシューティカルズ ゲーエムベーハー ワクチン接種に有用なt細胞エピトープの予測
JP2018515519A (ja) 2015-05-13 2018-06-14 アジェナス インコーポレイテッド がんの処置および予防のためのワクチン
JP2018524008A (ja) 2015-07-14 2018-08-30 パーソナル ジノーム ダイアグノスティクス, インコーポレイテッド ネオアンチゲン分析
WO2018136664A1 (en) 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN IMMUNOLOGY,2018年01月18日,VOL:8,1807,http://dx.doi.org/10.3389/fimmu.2017.01807
JOURNAL OF CLINICAL ONCOLOGY,2018年06月,VOL:36, NR:15 SUPPL,3100,http://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.3100
JOURNAL OF EXPERIMENTAL MEDICINE,2014年10月20日,VOL:211, NR:11,PAGE(S):2231-2248,http://dx.doi.org/10.1084/jem.20141308
NATURE,2017年07月13日,VOL:547, NR:7662,PAGE(S):217-221,402,http://doi.org/10.1038/nature22991

Also Published As

Publication number Publication date
JP2022502416A (ja) 2022-01-11
BR112021005702A2 (pt) 2021-06-22
IL281771B1 (en) 2025-04-01
MX2021003654A (es) 2021-05-28
AU2019346023A1 (en) 2021-03-25
BR112021005702A8 (pt) 2022-11-08
US12462898B2 (en) 2025-11-04
WO2020065023A1 (en) 2020-04-02
US20210388438A1 (en) 2021-12-16
CA3111903A1 (en) 2020-04-02
CN112771214A (zh) 2021-05-07
KR102902460B1 (ko) 2025-12-19
EP3856957A1 (en) 2021-08-04
IL281771B2 (en) 2025-08-01
CN112771214B (zh) 2025-06-13
KR20210065171A (ko) 2021-06-03
AU2019346023B2 (en) 2024-12-12
SG11202101965QA (en) 2021-04-29
IL281771A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
JP7585195B2 (ja) ネオエピトープを選択する方法
JP7530455B2 (ja) 新生抗原の特定、製造、及び使用
JP7651623B2 (ja) 新生抗原の特定、製造、及び使用
JP7755628B2 (ja) 新生抗原のためのジャンクションエピトープ提示の低減
EP2872653B1 (en) Personalized cancer vaccines and adoptive immune cell therapies
CA3217623A1 (en) Compositions and method for optimized peptide vaccines using residue optimization
TW201733598A (zh) 新抗原辨識、製造及用途
WO2020221783A1 (en) Methods for pre-selection of neoepitopes
KR20210064229A (ko) 신생항원-기반 면역요법을 위한 항원결정인자 표적화 방법 및 시스템
US20240021274A1 (en) Using neural networks to predict peptide immunogenicity
RU2826184C2 (ru) Способ отбора неоэпитопов
EP4437544A1 (en) Methods for predicting immunogenicity of mutations or neoantigenic peptides in tumors
HK40101953A (zh) 利用残基优化技术优化肽疫苗的组合物和方法
WO2025168848A1 (en) Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same
Ghesmati Immunoinformatics based designing of a multi-epitope peptide vaccine candidate against prostate cancer
HK40013532B (zh) 致免疫性的癌症特异抗原决定位的排名系统

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241106

R150 Certificate of patent or registration of utility model

Ref document number: 7585195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150